Alamar Biosciences, Inc. v. Olink Proteomics AB
Patent Trial and Appeal Board
Holding
On the parties' agreement, the Federal Circuit dismissed the appeal from the PTAB's decision in IPR2024-01353 under Fed. R. App. P. 42(b). Each side bears its own costs, and the order issued as the mandate.
Why It Matters
The appeal ends without any ruling on the merits, so the order offers no guidance. What happens to the underlying IPR outcome is not addressed in the order.
Full Summary
Key Points
- Alamar Biosciences appealed from the PTAB in IPR2024-01353; Olink Proteomics AB is the appellee.
- The parties agreed to dismissal, and the court dismissed the proceeding under Fed. R. App. P. 42(b).
- Each side shall bear its own costs.
- The order issued as the mandate on October 15, 2026.
- The order does not identify the patent, claims, or issues and decides nothing on the merits.
How this summary was made: Drafted with AI from the court's opinion or order; before publishing, code checked that the quotation and the citations it gives appear in that document. Editorial policy
New to District court litigation? Start with PTAB vs. District Court: Where to Challenge a Patent’s Validity
- Fed. Cir. · Oct. 16, 2026Micron Technology, Inc. v. Netlist, Inc.
- Fed. Cir. · Oct. 15, 2026Pictiva Displays International Ltd. v. Samsung Display Co., Ltd.
- Fed. Cir. · Oct. 14, 2026Syngenta Crop Protection AG v. UPL Ltd.
- Fed. Cir. · Oct. 14, 2026In re Speculative Product Design, LLC
- Fed. Cir. · Oct. 6, 2026Inari Agriculture, Inc. v. Corteva Agriscience LLC